Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Heterogeneous Computing and Solutions Provided by oneAPI 

Heterogenous computer systems – systems that contain different kinds of computational units (CPUs, GPUs, etc.) controlled by a general-purpose processor (GPP) and augmented by accelerators (XPUs) – are here to stay. However, the computational complexity inherent in these systems creates some unique challenges in the healthcare industry. In today’s “Health and Life Sciences at…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Heterogenous computer systems – systems that contain different kinds of computational units (CPUs, GPUs, etc.) controlled by a general-purpose processor (GPP) and augmented by accelerators (XPUs) – are here to stay. However, the computational complexity inherent in these systems creates some unique challenges in the healthcare industry. In today’s “Health and Life Sciences at the Edge” podcast, Intel’s Beenish Zia, Chief Architect for Medical Imaging in Intel’s Internet of Things Group, and Evgeny Drapkin, Chief Engineer for GE Healthcare Digital Platforms, talk with Tyler Kern about those challenges and solutions.

According to Drapkin, both the need for heterogeneous computing and the biggest challenges to its successful deployment can be illustrated by medical imaging. “In medical imaging, being able to deliver results from scans as quickly as possible is a necessity,” says Drapkin. “In many cases, like in stroke management, the speed of delivery can directly impact patient outcomes.” With the level of computational complexity growing every year, finding ways to increase image processing speeds is both imperative and challenging.

Enter heterogeneous computing using the Intel® oneAPI Toolkit. OneAPI is designed to meet the three biggest challenges developers and programmers face when creating heterogeneous systems:

  • Determining which hardware architecture to use
  • Selecting the proper software model
  • Porting legacy software in ways that take advantage of modern technologies

“OneAPI stands for One Application Programming Interface,” says Zia. “It simplifies software development and programming by providing a unified programming model. This model gives programmers the freedom to select the best hardware for their workloads, optimizes hardware performance, and removes hardware vendor lock-in.” Best of all, the same learning model applies to all industries and helps build community and industry collaboration.

Both Zia and Drapkin agree that heterogeneous computing is needed to identify and map algorithms to accelerator devices, then program those devices to deliver faster results. “Industries like medical imaging are driving the need for a common programming language that can transform how software coding is approached,” say Zia. “OneAPI provides a unified programming model that can be applied to all industries. Heterogeneous computing is inevitable. It’s up to us to optimize it.”

Connect with Beenish Zia and Evgeny Drapkin on LinkedIn.

More about how oneAPI could assist in heterogenous computing and rapid software deployment can be found at oneapi.io.

Subscribe to this channel on Apple Podcasts, Spotify, and Google Podcasts to hear more from the Intel Internet of Things Group.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512